Skip to content
Menu

Curis, Inc. CRIS

Full chart Compare
Set alert

Price alert · CRIS

All alert types
0.43 USD -0.04 (-9.03%)

Regular-session close

0.43 0.00 +0.70%

After hours · Nov 20, 4:38 PM ET

0.42 Day range 0.4936
0.33 52-week range 28.40
YTD
-97.84%
1 year
-98.02%

5D +0.0080 (+1.90%)

0.50000.6000MonTueWedThuFri0.4301
Market cap
4.06M
Revenue (ttm)
10.16M
EPS (ttm)
15.43
Shares out
8.47M
P/E ratio
0.03
Forward P/E
-0.77
YTD return
-97.84%
1-year return
-98.02%
50-day average
4.30
Volume
520.05K
Avg volume
4.33M
Open
0.471
Previous close
0.4694
Day's range
0.42 – 0.4936
52-week range
0.33 – 28.40
Beta
3.35
Analysts
Buy
Price target
21.00 (+4818.0%)

Key statistics

200-day average
7.78
Enterprise value
37.35M
Price / sales
2.71
Price / book
0.97
Revenue growth
15.90%
Free cash flow
-25.84M
Total cash
28.36M
Total debt
41.92M
Return on equity
-372.68%
Short % of float
2.28%

Fundamental scorecard

5 of 25 checks passed on CRIS’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 2 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 2 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
CRIS Revenue — quarterly 0
CRIS Net income — quarterly -8.12M
CRIS EPS — quarterly -1.94

Earnings

CRIS recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 13, 2025Dec 1, 2024-1.36———
Nov 14, 2024Sep 1, 2024-1.88-1.70+0.18+9.57%
Aug 1, 2024Jun 1, 2024-1.70-2.03-0.33-19.41%
May 7, 2024Mar 1, 2024-1.94-2.05-0.11-5.67%
Feb 8, 2024Dec 1, 2023-1.91-2.03-0.12-6.28%
Nov 2, 2023Sep 1, 2023-2.32-2.13+0.19+8.19%

Upgrades / downgrades

CRIS analyst upgrades and downgrades
DateFirmActionFromTo
Dec 10, 2024HC Wainwright & Co.reitBuyBuy
Nov 15, 2024HC Wainwright & Co.reitBuyBuy
Nov 1, 2024HC Wainwright & Co.mainBuyBuy
Aug 1, 2024HC Wainwright & Co.reitBuyBuy
May 15, 2024Truist SecuritiesmainBuyBuy
May 15, 2024HC Wainwright & Co.reitBuyBuy

About Curis, Inc.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
curis.com

News

Your note

Sign in to keep a note on CRIS — it syncs with the Stock Master app.

Institution ownership

CRIS institution ownership
Holder% heldSharesValueReported
Maverick Capital Ltd.6.88%582,2731.89MSep 29, 2024
M28 Capital Management LP4.98%421,9511.37MSep 29, 2024
Vanguard Group Inc3.24%274,681892.71KSep 29, 2024
CM Management, LLC1.42%120,000390.00KSep 29, 2024
Renaissance Technologies, LLC1.11%93,772304.76KSep 29, 2024
Citigroup Inc.1.09%91,872298.58KSep 29, 2024

Fund ownership

CRIS fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.19%185,441602.68KSep 29, 2024
Vanguard Extended Market Index Fund0.96%81,339264.35KSep 29, 2024
Fidelity Extended Market Index Fund0.40%33,521108.94KOct 30, 2024
iShares Micro Cap ETF0.16%13,42543.63KOct 30, 2024
Northern Small Cap Core Fund0.14%11,80038.35KSep 29, 2024
Fidelity Total Market Index Fund0.12%10,20833.18KOct 30, 2024